Results for Combination Bevacizumab Plus Mirvetuximab Soravtansine in Ovarian Cancer
August 23rd 2018David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
Watch